Kite Pharma, a California-based biopharmaceutical company that develops cancer immunotherapies, recently announced plans to open a new biologics manufacturing facility in Frederick County, Md.
The facility will produce cell therapies for people with cancer.
A Gilead company, Kite will open the new facility on a 20-acre site in Urbana. The company said it has “plans to create significant job opportunities.”
“This new facility in Urbana builds on our substantial technical capabilities and rapid progress in making personalized chimeric antigen receptor T and T cell receptor cell therapies for people with cancer,” Tim Moore, executive vice president of technical operations at Kite, said in a news release.
“As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essential. With the Urbana site, we will have the opportunity to build and design the facility tailored to our own innovative processes and with state-of-the-art features that will enable us to meet the future needs for cell therapies.”
The new Frederick County facility will become part of Kite’s growing commercial manufacturing network that includes sites in California and the Netherlands.
To assist with project costs, the Maryland Department of Commerce has approved a $2 million conditional loan through the Advantage Maryland Fund (formerly known as the Maryland Economic Development Assistance Authority and Fund) and a $200,000 workforce training grant through the Partnership for Workforce Quality program.
In addition, Frederick County is providing a Commercial and Industrial Tax Credit, which is offered to new and expanding businesses that focus on manufacturing, fabricating and assembly. The company is also eligible for various state and local tax credits, including the Job Creation Tax Credit and the More Jobs for Marylanders Tax Credit, which incentivizes manufacturers to create new jobs in the state.